GE HealthCare selects AWS as its strategic cloud provider to deliver entirely new, purpose-built foundation models designed to fast-track the development of innovative healthcare applications
GE HealthCare plans to train and deploy clinical foundation models on AWS’s machine learning and generative AI technologies to help healthcare providers expedite clinical and operational workflows to improve delivery of care CHICAGO / Jul 25, 2024 / Business Wire / GE HealthCare... Read more
Focus on clinically-led features, including new AI smart notes to assist providers NEW YORK / Jul 24, 2024 / Business Wire / Talkspace (NASDAQ: TALK), a leading online behavioral health care company, today announced the formation of the dedicated AI Innovation Group aimed at advancing provider efficiency, and enhancing clinical quality and overall operational excellence through responsible and ethical use of artificial intelligence. Created in partnership with Talkspace’s... Read more
DALLAS, July 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced a 30% increase in its patent portfolio that strengthens and protects its proprietary, AI-driven DeepView System wound assessment platform.
Total patents granted to the Company increased to 26 through July... Read more
REDWOOD CITY, CA / ACCESSWIRE / July 22, 2024 / Biotricity Inc. (Nasdaq:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced ongoing improvements in operational efficiency, scalability and margin performance driven by the latest enhancements to the company's proprietary AI Cloud platform.
The latest version of Biotricity's AI Cloud has improved the company's tech stack efficiency by 20%,... Read more
Agreement to acquire business adds innovative, real-time image recognition technology and expertise to GE HealthCare’s portfolio of AI-enabled devices
AI-based technology from Intelligent Ultrasound aims to provide real-time support for OBGYN scans and improve exam accuracy and efficiency
Planned acquisition supports GE HealthCare’s precision care strategy to address inefficiencies and improve patient care quality CHICAGO / Jul 18, 2024 / Business Wire / GE HealthCare... Read more
The total number of Hyperfine AI-powered marketing authorizations places the company in a leading position on recently published FDA list. GUILFORD, Conn. / Jul 17, 2024 / Business Wire / Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance brain imaging system—the Swoop® system—today announced the clearance of the ninth generation of AI-powered Swoop®... Read more
WELL has launched its new AI-powered physician co-pilot to assist cardiologists in better identifying patients at high risk of cardiovascular disease ("CVD"). WELL is exclusively partnering with HEALWELL AI, a leader in AI enabled disease diagnosis, as an extension of the WELL AI Decision Support ("WAIDS") product offering.
The co-pilot will be deployed into WELL Diagnostic Centres, Canada's largest cardiology and medical diagnostic group, providing support and assisting... Read more
Available Today for Life Science Research Use Only CHICAGO / Jul 16, 2024 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based portfolio being developed at Tempus to bring next-generation algorithmic diagnostics to the immuno-oncology... Read more
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform
Improved Performance: Utilizing a state-of-the-art novel deep-learning framework as well as training on public and proprietary data, Evaxion has improved the performance of EvaxMHC compared to publicly available tools
Precision in Vaccine Target Prediction: These advancements in EvaxMHC’s performance are anticipated... Read more
WELL Health and its consortium partners have been awarded the largest DIGITAL project to date for Health Compass II, an initiative that will continue the advancement of AI and interoperability in Canadian healthcare.
WELL Health will not only serve as the lead commercialization partner and first customer, but will also provide expertise and interoperability to each consortium partner for an unprecedented opportunity to innovate and develop new AI tools to better support... Read more
State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost OXFORD, England / Jul 10, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced it will be expanding its work with Amazon Web Services (AWS) to use the cloud provider’s artificial intelligence (AI)... Read more
P3 Health Partners will utilize Innovaccer’s Healthcare AI Platform for personalized interventions, improved outcomes, and cost-effective healthcare delivery for their patients. SAN FRANCISCO / Jul 09, 2024 / Business Wire / Innovaccer Inc., a leading healthcare AI company, announced a new strategic partnership with P3 Health Partners, (NASDAQ: PIII), a patient-centered, physician-led population health management company revolutionizing care delivery for Medicare patients.... Read more
CHICAGO / Jul 08, 2024 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the company’s PurISTSM algorithmic test has received a proprietary laboratory analysis (PLA) code from the American Medical Association (AMA). The new code will be effective on October 1, 2024. The PurISTSM PLA code is the first common procedural terminology (CPT) code created to describe an algorithm-only analysis from... Read more
Leveraging Butterfly Network's platform, UltraSight seeks to enable patients to access cardiac imaging with real-time AI guidance TEL AVIV, Israel, June 27, 2024 /PRNewswire/ -- Today, UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial intelligence, announced it has joined Butterfly Garden, an artificial intelligence (AI) Marketplace launched by Butterfly Network, Inc. ("Butterfly") (NYSE: BFLY), a digital health... Read more
DALLAS, June 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has surpassed 90% of the enrollment target for pediatric patients at burn centers for its 2024 pivotal study designed to validate the AI-driven algorithm used by its DeepView™ System for its burn... Read more
DURHAM, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the launch of its artificial intelligence (AI) Innovation Studio, signaling a strategic investment in reshaping the execution of clinical trials today and into the future.
The studio will develop and deploy AI and machine learning (ML) technologies to drive speed, agility, quality and enhanced patient safety in the clinical research... Read more
CHICAGO / Jun 26, 2024 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF device that uses AI to help identify patients who may be at increased risk of atrial fibrillation/flutter (AF). This is the first FDA clearance for an AF indication in the category known as “cardiovascular machine learning-based... Read more
Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention
Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive nature of all relevant claims in the application, distinguishing the invention in the field of personalized cancer vaccines
Strengthened Position: The patentability report reinforces Evaxion’s strong stance... Read more
HEALWELL completes USD $2,000,000 strategic investment into an xAI investment vehicle as part of its capital allocation strategy where it seeks to enhance and accelerate the development of its healthcare focused data science capabilities by partnering with world class platforms and seeking opportunities to integrate them with its own proprietary data and technology.
HEALWELL has made this investment through Think 1st Principles ("T1P"), an investment fund founded by... Read more
INDIANAPOLIS, June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens. Antimicrobial resistance (AMR) is one of the top public health and development threats across the global health landscape.
"Our collaboration with OpenAI represents a groundbreaking step forward in the fight against the growing but overlooked... Read more
VICTORIA, British Columbia / Jun 25, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand, is collaborating with PGxAI to leverage BioStrand's patented Foundation AI Model, LENSai. This collaboration advances the precision medicine field of pharmacogenomics and supports LENSai Application Programming Interface (“API”)... Read more
Toronto, Ontario – TheNewswire - June 24, 2024 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has been selected to present its AI-enhanced cardiac ultrasound technology, which generates MRI-quality cardiac measurements in minutes, to health-care leaders at The Data Effect on June 25th in Vancouver.
CEO Hugh MacNaught will be on the panel Accelerating AI Startups in Canadian Health Care, which explores applications of AI and digital... Read more
PURCHASE, NY, June 24, 2024 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, released new data today from two studies, presented at the American Diabetes Association’s 84th Scientific Sessions, that illustrate the company’s unmatched predictive modeling capabilities to help members with type 2 diabetes control their blood sugar through participation in Teladoc Health’s diabetes management program.
The new data shows... Read more
Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nomination
Bayer to become first external beta-user of LOWE (LLM-Orchestrated Workflow Engine) for drug discovery and development SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give... Read more
Pentavere collaborated with Princess Margaret Cancer Centre's Radiation Oncology Department to assess the feasibility and accuracy of DARWEN™ AI to find patients experiencing radiation related toxicities based on information retrieved from electronic health records.
The data and results from this groundbreaking AI research collaboration have been accepted for presentation at the American Society for Radiation Oncology in Washington DC on September 29th and the Canadian... Read more
SAN FRANCISCO, June 20, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, announced today that Emergency Services Inc., a physician-owned emergency medicine services group in Columbus, Ohio, is introducing Augmedix Go ED to physicians in the emergency department (ED) at the second-largest healthcare system in central Ohio.
Augmedix Go ED is the industry’s first fully automated, generative AI (GenAI) powered... Read more
RADNOR, Pa., June 17, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers. It combines generative AI, document templates, Microsoft Word integration, and structured content authoring tools. CoAuthor accelerates the creation of regulatory documents while maintaining a “human... Read more
Venlo, the Netherlands, and Redwood City, California, June 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the release of a new version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), that brings significant performance and scalability enhancements tailored for high-throughput, next-generation sequencing (NGS) labs moving to larger test panels and higher test volumes. The latest... Read more
Enhancements address significant clinical enterprise need in wearables for a variety of healthcare applications PLEASANTON, Calif., June 13, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced major advances in the accuracy of its heart rate in motion algorithm following the implementation of deep learning into the processing. The Company recently released an engineering accuracy study directed by Movano Health Founder and CTO Michael Leabman, Enhanced... Read more
Toronto, Ontario--(Newsfile Corp. - June 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A) ("Telo" or the "Company"), is pleased to announce that results of the development, validation and implementation of its machine learning and Artificial Intelligence (AI) modules, used in its TeloView myeloma diagnostic tests, were presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting that took place in Chicago, USA between May 30-June... Read more
DURHAM, N.C. and WARSAW, Ind., June 12, 2024 /PRNewswire/ -- RevelAi Health and Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a multi-year co-marketing agreement to commercialize generative artificial intelligence (AI)-powered engagement solutions that advance value-based orthopedic care and health equity. During the multi-year agreement, Zimmer Biomet will commercialize RevelAi Health's patient care-management platform,... Read more
HEALWELL enters into an agreement to acquire VeroSource Solutions Inc. and its end-to-end, customizable, cloud-based platform that enables patients, care providers and administrators to seamlessly access and interact with healthcare data.
VeroSource currently serves five provincial health clients and is expected to generate over $8 million in revenues in 2024 with an expected EBITDA1 margin of over 10%. Historically, VeroSource has achieved a 3-year revenue CAGR2 of... Read more
Nvidia BioNeMo generative AI platform will be used to accelerate the training of models on proprietary data NEW YORK, June 10, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a joint development agreement with Wise Systems International SRL to leverage artificial intelligence utilizing the BioNeMo AI platform of Nvidia.
BioNeMo provides researchers and developers a... Read more
BioStrand now offers a Customizable Application Programming Interface (API) with its new software offering, LENSai API, featuring the ability to integrate sizable databases and electronic health records with large language models.
BioStrand’s novel software is rapidly and directly integrable into pharmaceutical, healthcare, and technology companies to enhance drug discovery capabilities.
This proprietary software provides the integration of electronic health records,... Read more
SINGAPORE, June 06, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or “the Company”), a leading Asia-Pacific telehealth provider, today announces the latest major update to its cloud-based MaNaDr AI-Powered Health Operating System (“MHOS”) designed to transform healthcare delivery on a global scale.
Streamlined Operations, Enhanced Care
The latest MHOS boasts a suite of powerful features that empower clinics to significantly... Read more
Pentavere’s partnership with Takeda to pioneer real-world evidence analysis for HAE patients, addressing critical gaps in treatment understanding.
This innovative research collaboration has generated one of the largest cohort data sets globally of HAE with normal C1 inhibitor and will be utilized in enhancing patient outcomes through better understanding of current treatment use and clinical outcomes.
This partnership and commercial engagement builds upon Pentavere... Read more
Nanox integrates FDA-cleared population health AI solutions into its Second Opinions service
New AI capabilities available to patients who submit chest and abdominal CT scans for second opinions
Offering the power of Artificial Intelligence to their second opinion CT report to promote early detection of chronic conditions PETACH TIKVA, Israel, June 05, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative... Read more
Predictive Oncology’s organ-specific in vitro models are designed to better mimic the physiological environment of human tissue
The 3D cell culture market is projected to grow by more than 14% annually, from $1.4 billion in 2022 to nearly $5.3 billion annually by 20321 PITTSBURGH, June 04, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced the availability... Read more
Dirk Van Hyfte MD, PhD, Head of Technology, IPA, to present live demonstration at the InterSystems Global Summit 2024 June 9-12, 2024 - National Harbor, Maryland VICTORIA, British Columbia / Jun 04, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that its Belgian subsidiary, BioStrand, is leveraging their patented... Read more
Machinify solution seeks to accelerate the efficiency, quality, and clinical value of Evolent's specialty condition management platform through AI-enabled clinical workflow automation
Machinify technology leverages the latest advances in applied machine learning, large language models and data analytics
Acquisition expected to benefit health plans, clinicians, and members WASHINGTON, June 4, 2024 /PRNewswire/ -- Evolent Health, Inc. ("Evolent" or "the Company"),... Read more
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Jefferies Healthcare Conference - June 5-6, 2024
45th Annual Goldman Sachs Healthcare Conference - June 10-13, 2024
Morgan Stanley 3rd Annual Life Sciences AI Summit - June 26-27, 2024 About Recursion
Recursion is a clinical... Read more
Tempus, a leader in artificial intelligence and precision medicine, today announces a suite of new features in its physician platform, Hub. Trusted by thousands of oncologists and care teams, Hub is an AI-enabled platform that provides access to patient insights in a secure environment. Tempus is now unveiling a collection of new and enhanced features designed to make it easier for clinicians to access each of their patient’s comprehensive profiles to better inform... Read more
Tempus, a leader in artificial intelligence and precision medicine, today announces a suite of new features in its physician platform, Hub. Trusted by thousands of oncologists and care teams, Hub is an AI-enabled platform that provides access to patient insights in a secure environment. Tempus is now unveiling a collection of new and enhanced features designed to make it easier for clinicians to access each of their patient’s comprehensive profiles to better inform... Read more
SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics scientific findings that highlights a potential limitation of CRISPR-Cas9 in gene editing - a key component in understanding disease mechanisms, and developing new therapeutic approaches.
This proximity bias, discoverable through Recursion’s proprietary biological dataset,... Read more
In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole genome analytical solution BOSTON and ROLLE, Switzerland, May 29, 2024 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that it is collaborating with Microsoft and NVIDIA to leverage their expertise in technology and genomics to bring a streamlined and scalable whole... Read more
Study paves the way toward a first-ever innovation program to include AI-optimization for FDA-guided Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces the successful completion of a Formative Human Factors study of its AI-integrated Web App, designed to facilitate... Read more
SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an innovative, artificial intelligence driven, breast cancer risk assessment model. The SMART (Stockholm MAmmography Risk stratified Trial) study will test an individualized, imaging-based screening model designed to identify women with the highest risk of developing breast cancer in... Read more
SALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert Hershberg, M.D., Ph.D, has been appointed the new Chair of the Board of Recursion, effective at the end of this term, as Martin Chavez exits after more than four years of leadership.
“I’m excited to bring my clinical and scientific expertise to support Recursion’s growth as... Read more
Pentavere partnered with Sunnybrook Health Sciences Centre to demonstrate how Pentavere’s DARWEN™ AI platform can help enhance cancer staging to improve patient outcomes.
Results of this collaboration were presented at the prestigious American Head and Neck Society annual conference and published in JAMA Otolaryngology, which is the highest impact journal for Otolaryngologic or ‘head and neck’ cancers.
This is the first published paper of its kind demonstrating... Read more
Southlake, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has been granted Indian Patent Application 201817014481 by the Indian Patent Office (IPO).
To date, HeartSciences has been... Read more